Champions Oncology, Inc. (NASDAQ: CSBR) Reports Q1 Revenue Growth and Improved Adjusted EBITDA

• Champions Oncology, Inc. reported adjusted earnings per share of $0.05, exceeding the consensus estimate of a $0.01 loss per share.
• Revenue increased 8.8% year over year, driven primarily by improved execution in the company’s core research services business.
• Despite reporting a GAAP net loss, adjusted EBITDA increased substantially, reflecting stronger margins and improved non-GAAP operating performance.

Champions Oncology, Inc. (NASDAQ: CSBR) is a translational oncology research organization that provides cancer-drug discovery and development services to biopharmaceutical companies. Its services include preclinical and clinical research solutions supported by patient-derived xenograft models, bioanalytical platforms, and oncology data. The company also operates a data licensing business that provides information and analytical tools for cancer research.

On September 10, 2026, Champions Oncology, Inc. reported its first-quarter fiscal 2027 results for the period ended July 31, 2026. The company recorded adjusted earnings per share of $0.05, exceeding the consensus estimate of a $0.01 loss per share. On a GAAP basis, however, Champions Oncology reported a loss of $0.03 per share.

The company generated revenue of $15.23 million, surpassing the estimated $15.05 million. Revenue increased 8.8% from approximately $14.00 million in the same period last year. The growth was driven primarily by improved execution and conversion of contracted work within the company’s core research services business, together with increased data licensing revenue.

Champions Oncology reported a GAAP net loss of approximately $426,000, compared with a net loss of $466,000 in the prior-year period. Meanwhile, adjusted EBITDA, a non-GAAP profitability measure, increased to $671,000 from $59,000. The company’s oncology services margin also improved to 51% from 43%, reflecting higher revenue and lower third-party radiolabeling costs.

Although adjusted EBITDA improved considerably, it should not be interpreted as operating cash flow. Champions Oncology used approximately $492,000 in operating cash during the quarter, primarily because of normal working-capital movements. The company ended the period with approximately $4.36 million in cash and no debt.